AI Automated Translation.

Font Size

Share

Reyon Pharmaceutical nears global CMO deal worth 700 billion won over 10 years

Reyon Pharmaceutical nears global CMO deal worth 700 billion won over 10 years

Reyon Pharmaceutical's Chungju Plant / Graphic by Lee Ji-hye
Reyon Pharmaceutical's Chungju Plant / Graphic by Lee Ji-hye

A global contract for the commissioning of pharmaceutical production (CMO) by Reyon Pharmaceutical is imminent. As a long-term contract of up to more than 10 years, the total revenue scale is expected to exceed 700 billion won.

This means that the full-scale operation of the Chungju Smart Plant, which is a future growth driver for Reyon Pharmaceutical, is just around the corner.

According to industry sources on Friday, it has been confirmed that negotiations for Reyon Pharmaceutical's global CMO contract have entered their final stages.

The company is currently in the process of adjusting the details of the definitive contract. While specific products cannot be disclosed due to the counterparty and confidentiality conditions, it is known that production will take place in the chemical division of the Chungju Plant.

In particular, Reyon Pharmaceutical's first global CMO contract is understood to be a long-term transaction of more than 10 years. The counterparty has already completed an on-site audit, and the Chungju Plant is currently undergoing equipment expansion for commercial production under this CMO contract. The signing of the definitive contract is expected as early as within this year or in early next year.

Reyon Pharmaceutical plans to begin trial operations around next summer after signing the CMO definitive contract. The timing of full-scale revenue generation is estimated to be in the fourth quarter of 2028. This is because the counterparty will change the production location of the pharmaceuticals, necessitating a new process for obtaining regulatory approvals.

With this CMO contract, Reyon Pharmaceutical is projected to generate annual revenues of 40 billion to 50 billion won starting in 2029. As the company plans to expand the approved regions for the produced pharmaceuticals to major markets including Japan, there is a possibility that annual revenue will increase over time. The estimated total cumulative revenue over 10 years is projected to be more than 700 billion won.

To strengthen its future growth drivers, Reyon Pharmaceutical invested approximately 350 billion won to complete the Chungju Plant in 2021.

Following KGMP (Korean Good Manufacturing Practice) certification in August 2023, the Chungju Plant obtained specialized contract GMP (Good Manufacturing Practice) certification for biopharmaceuticals in November 2024. It is capable of producing everything from raw materials to finished products for various substances, including Plasmid DNA, non-viral and viral vectors, and mRNA (messenger ribonucleic acid).

Based on the Chungju Plant, Reyon Pharmaceutical is expanding collaboration opportunities both domestically and internationally while simultaneously working to improve its financial structure through partial asset monetization.

A company official said, "We are continuing negotiations for a CMO contract to enhance the strategic value of the Chungju Plant. We are currently unable to disclose specific contract terms."

The official noted, "However, if the CMO contract is concluded, it will serve as an opportunity for the Chungju Plant to transform into a global pharmaceutical production facility."

"This article was translated using AI and may differ slightly from the original."